Publication
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.
Martin F Kaiser, Rachel H Phillip, Sarah R Brown, Amy Holroyd, Elsa Ferris, Ruth M de Tute, Sadie Roberts, Laura Clayton, Kristian Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S Houlston, Graham Jackson, Gordon Cook, Roger G Owen, Mark T Drayson, Guy Pratt, Andrew Hall, Matthew W Jenner
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: High-risk multiple myeloma, defined by two or more high-risk cytogenetic abnormalities (HRCAs), high-risk gene expression profiling (GEP), or plasma cell leukaemia, remains associated with poor long-term outcomes despite quadruplet induction therapy. OPTIMUM showed that intensified…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03188172registry_reference1.00
Candidate 1
- cancerMultiple Myelomadictionary0.60
Registered trialsNCT03188172
Curated evidence
Evidence citing this paper (0)
Data not yet available